Cefepime has been hard to find due to ongoing shortages. Learn why this hospital antibiotic is in short supply and what you can do about it in 2026.
If you or a loved one has been prescribed Cefepime and the hospital pharmacy or outpatient infusion center is telling you it's on backorder, you're not alone. Cefepime — a powerful IV antibiotic used to treat serious infections — has been affected by recurring supply disruptions that have left patients and healthcare providers scrambling for alternatives.
In this guide, we'll break down exactly what Cefepime is, why it keeps running into shortage problems, and what steps you can take to make sure you get the treatment you need.
Cefepime (brand name Maxipime, now discontinued) is a fourth-generation cephalosporin antibiotic that belongs to the beta-lactam class of drugs. It works by disrupting bacterial cell wall synthesis, which ultimately kills the bacteria causing an infection.
Doctors prescribe Cefepime to treat a wide range of serious infections, including:
Cefepime is only available as an injection or IV infusion. It cannot be taken as a pill or liquid by mouth. This means it's typically given in hospitals, outpatient infusion centers, or through home IV therapy programs.
To learn more about what this medication does, check out our full guide: What Is Cefepime? Uses, Dosage, and What You Need to Know.
The Cefepime shortage isn't caused by a single problem — it's the result of several overlapping issues in the pharmaceutical supply chain. Here are the main reasons this essential antibiotic has been difficult to source.
Cefepime is a sterile injectable medication, which means it must be produced under extremely strict manufacturing conditions. Sterile injectable drugs are among the most shortage-prone medications in the United States. According to the American Society of Health-System Pharmacists (ASHP), over half of all drug shortages involve sterile injectables.
When a manufacturer encounters quality control issues, equipment failures, or contamination concerns, production can halt for months. Because Cefepime requires specialized facilities to produce, it's especially vulnerable to these disruptions.
The market for generic sterile injectables has thin profit margins, which has driven some manufacturers out of the market. Sandoz, one of the major Cefepime producers, discontinued its Cefepime injection line in early 2016. The original brand-name product, Maxipime (made by Pfizer), has also been discontinued.
When fewer companies produce a drug, a single manufacturing problem at one facility can create a nationwide shortage. The remaining manufacturers — including Hospira/Pfizer, Baxter, B. Braun, Hikma, and Sagent — sometimes cannot ramp up production quickly enough to fill the gap.
Hospital demand for broad-spectrum IV antibiotics like Cefepime can spike during flu seasons, respiratory infection outbreaks, or when antibiotic resistance patterns shift. When hospitals need more Cefepime than usual, existing supplies get stretched thin. This is made worse by the fact that many hospitals don't stockpile large reserves of injectable antibiotics.
Even when Cefepime is being manufactured, distribution challenges can create localized shortages. Raw material sourcing, shipping delays, and allocation limits placed by distributors can mean that some hospitals receive their orders while others wait weeks.
If Cefepime has been prescribed for you or a family member and you're having trouble getting it, here are some practical steps:
Several other antibiotics can treat many of the same infections as Cefepime. Depending on the specific bacteria involved, your doctor may consider switching to alternatives like Piperacillin-Tazobactam (Zosyn), Meropenem, or Ceftazidime. Your doctor will check the culture and sensitivity results to make sure a substitute will work for your infection.
Rather than calling pharmacy after pharmacy, use Medfinder to quickly check which facilities near you have Cefepime in stock. This can save valuable time when you need treatment urgently. For more tips, see our guide on how to find Cefepime in stock near you.
If the hospital pharmacy is out of stock but you're stable enough for outpatient treatment, ask your care team about home infusion pharmacies. These specialty pharmacies sometimes have access to different supply channels and may be able to source Cefepime when hospital pharmacies cannot.
Hospital pharmacists are often the first to know about drug shortages and may have already developed protocols for managing Cefepime supply issues. They can work with your doctor to find the best available option and may be able to obtain the drug through alternative distributors.
Drug shortages for sterile injectables tend to be cyclical. Supply may improve for a period and then tighten again when manufacturing issues arise. The FDA monitors Cefepime availability and works with manufacturers to address shortages, but there's no simple fix for the underlying structural problems in the sterile injectable market.
For the latest updates on Cefepime availability, check out our Cefepime shortage update for 2026.
Cefepime is an essential antibiotic for treating serious bacterial infections, and not being able to find it can be genuinely frightening — especially when you or a loved one is seriously ill. The shortage is driven by manufacturing complexity, fewer producers, and unpredictable demand surges.
The good news is that alternatives exist, your healthcare team is trained to navigate these situations, and tools like Medfinder can help you locate available supply faster. Stay in close communication with your doctor and pharmacist, and don't hesitate to ask questions about your treatment options.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
